PER-074-09已完成未知

A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3

INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS,0 个研究点目标入组 0 人开始时间: 2009年10月12日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•HIV-infected.
•Confirmed or probable TB (more information on the criterion can be found in the protocol).
•Chest x-ray within 30 days prior to study entry.
•Receipt of 1-14 cumulative days of rifampin- or other rifamycin-based TB treatment that was initiated within 28 days prior to study entry.
•CD4 count less than 250 cells/mm^3 within 30 days prior to study entry.
•Willing to use acceptable methods of contraception while on study drugs and for 6 weeks after stopping these drugs.
•Able to swallow oral medications.
•Parent of guardian willing to provide informed consent, if applicable.
•Karnofsky performance score =>20 at time of study entry.

•ART for longer than 7 cumulative days prior to study entry or treatment for any period of time with one or more antiretrovirals. Participants who have taken ART during pregnancy or for occupational exposure are not excluded.
•Allergy or sensitivity to any of the study drugs or their formulations.
•History of multidrug-resistant TB.
•Receipt of any investigational therapy or chemotherapy within 30 days prior to study entry.
•Certain medications.
•Breastfeeding.

发起方

INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS,